RecruitingPhase 3NCT05596786

Evaluation of Efficacy and Safety of Rituximab in Patients With Progressive Interstitial Lung Disease (ILD) With Inflammatory Component: a Multicentre Double-blind Placebo-controlled Randomized Trial

Studying Interstitial lung disease

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
University Hospital, Tours
Principal Investigator
Julien LE BONNIEC
University Hospital Center of Tours
Intervention
Rituximab(drug)
Enrollment
126 target
Eligibility
18-100 years · All sexes
Timeline
20232026

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05596786 on ClinicalTrials.gov

Other trials for Interstitial lung disease

Additional recruiting or active studies for the same condition.

See all trials for Interstitial lung disease

← Back to all trials